Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment

References

• Alberts D. S., Peng Y.-M., Chen H.-S. G., Moon T. E., Cetas T. C., Hoeschele J D. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. Journal of the National Cancer Institute 1980; 65: 455–461
   PubMed Web of Science ®Google Scholar
• Baldew G. S., van den Hamer C. J. A., Los G., Vermeulen N. P. E., De Goeu J. J. M., McVie J. G. Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats. Cancer Research 1989; 46: 3020–3023
   Google Scholar
• Bodenner D. L., Dedon P. C., Keng P. C., Katz J. C., Borch R. F. Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbonate. Cancer Research 1986; 46: 2751–2755
   PubMed Web of Science ®Google Scholar
• Gerad H., Egorin M. J., Whitacre M., Van Echo D. A., Aisner J. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum (II) and whole-body hyperthermia. Cancer Chemotherapy and Pharmacology 1983; 11: 162–166
   PubMed Web of Science ®Google Scholar
• Green D. M., Burton G. V., Cox E. B., Hanson D., Moore J., Oleson J. R. A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy. International Journal of Hyperthermia 1989; 5: 13–21
   PubMed Web of Science ®Google Scholar
• Herman T. S., Thicker B. A. Sequencing of trimodality therapy [cis-diammine-dichloroplatinum(II/Hyperthermia/Radiation] as determined by tumor growth delay and tumor cell survival in the FSallC fibrosarcoma. Cancer Research 1988; 48: 2693–2697
   PubMed Web of Science ®Google Scholar
• Issels R. D., Prenninger S. W., Nagele A., Boehm E., Sauer H., Jauch K.-W., Denecke H., Berger H., Peter K., Wilmanns W. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. Journal of Clinical Oncology 1990; 8: 1818–1829
   PubMed Web of Science ®Google Scholar
• Lindegaard J. C., Radacic M., Khalil A. A., Horsman M., Overgaard J. Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose and temperature. Acta Oncologica 1992; 31: 347–351
   PubMed Web of Science ®Google Scholar
• Mella O. Combined hyperthermic and cis-diamminedichloroplatinum in BD IX rats with transplanted BT4A tumours. International of Journal Hyperthermia 1985; 1: 171–183
   PubMedGoogle Scholar
• Mella O., Eriksen R., Dahl O., Laerum O. D. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat. European Journal of Cancer 1987; 23: 365–373
   Google Scholar
• Ouzumi J., Sagiyama K., Aoki K., Iwamoto Y., Baba T. Effectiveness of “two-route chemotherapy” using cisplatin and its antidote sodium thiosulphate, on lifespan of rats bearing metastatic liver tumors. Cancer Treatment Report 1983; 67: 1067–1074
   PubMedGoogle Scholar
• Overgaard J. Effect of local hyperthermia on the acute toxicity of misonidazole in mice. British Journal of Cancer 1979; 39: 96–98
   PubMed Web of Science ®Google Scholar
• Overgaard J. The current and potential role of hyperthermia in radiotherapy. International Journal of Radiation Oncology, Biology and Physics 1989; 16: 535–549
   PubMed Web of Science ®Google Scholar
• Overgaard J. The future of hyperthermic therapy. Hyperthermic Oncology 1992. Proceedings of the 6th International Congress on Hyperthermic Oncology, E. W. Gerrer. Arizona Boards of Regents, 1992; Vol. 2, (in press)
   Google Scholar
• Overgaard J., Radacic M., Grau C. Interaction of hyperthermia and cis-diamminedichloroplatinum (II) alone or combined with radiation in a C3H mammary carcinoma. Cancer Research 1991; 51: 707–711
   PubMed Web of Science ®Google Scholar
• Radacic M., Boranic M., Skaric D., Skaric V., Mihalic H., Gajsak V., Jercic J., Lelieveld P. Reduction of cis-dichlorodiammineplatinum (II) caused nephrotoxicity by indazolone carboxilic acid. Oncology 1987; 44: 34–37
   PubMed Web of Science ®Google Scholar
• Radacic M. M., Overgaard J., Skaric D., Skaric V., Horsman M. R. Reduction of cisplatinum-induced renal toxicity in mice by tetrahydraindazolone carboxylic acid (HIDA). Acta Oncologica 1993; 32: 53–56
   PubMed Web of Science ®Google Scholar
• Skaric D., Skaric V., Turjak-Zebic V. 4,5,6,7-Tetrahydroindazol-3-one carboxylic acids. III. Reductive cleavage related to conformational analysis of 2-carboxamide-4,4-dicarbethoxy-cyclohexamide. Croatia Chemica Acta 1963; 35: 267–273
   Google Scholar
• Treskes M., Boven E., Holwerda U., Pinedo H. M., Van Der Vijgh W. J. F. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Research 1992; 52: 2257–2260
   PubMed Web of Science ®Google Scholar
• Turjak-Zebic V., Skaric D., Skaric V. 4,5,6,7-tetrahydroindazol-3-one carboxilic acids. VI. Complexing behavior of 5,5-dicarboxylic acid with divalent ions. Croatia Chemica Acta 1969; 41: 235–243
   Google Scholar
• van Hennik M. B., Van der Vigh W., Klein I., et al. Comparative pharmacokinetics of cisplatin and three analogues in mice in humans. Cancer Research 1987; 47: 6297–6301
   PubMed Web of Science ®Google Scholar
• Wallner K. E., Degregorio M. W., Li G. C. Hyperthermic potentiation of cis diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Research 1986; 46: 6242–6245
   PubMed Web of Science ®Google Scholar
• Wondergem J., Burger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephens L. C., Bull J. M. Effect of cis-diamminedichloroplatinum (II) combined with whole body hyperthermia on renal injury. Cancer Research 1988; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Xu M. J., Alberts D. S. Potentiation of platinum analogue cytotoxicity by hyperthermia. Cancer Chemotherapy and Pharmacology 1988; 21: 191–196
   PubMed Web of Science ®Google Scholar